Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast‑like giant cells: A case report

  • Sasaki T
  • Kawashima H
  • Ariizumi T
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.

Cite

CITATION STYLE

APA

Sasaki, T., Kawashima, H., Ariizumi, T., Yamagishi, T., Oike, N., Umezu, H., … Ogose, A. (2017). Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast‑like giant cells: A case report. Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2017.1489

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free